Logo image of AYTU

AYTU BIOPHARMA INC (AYTU) Stock Fundamental Analysis

USA - NASDAQ:AYTU - US0547548588 - Common Stock

2.25 USD
-0.02 (-0.88%)
Last: 10/23/2025, 10:44:43 AM
Fundamental Rating

2

AYTU gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. While AYTU is still in line with the averages on profitability rating, there are concerns on its financial health. AYTU has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year AYTU has reported negative net income.
In the past year AYTU has reported a negative cash flow from operations.
In the past 5 years AYTU always reported negative net income.
In the past 5 years AYTU always reported negative operating cash flow.
AYTU Yearly Net Income VS EBIT VS OCF VS FCFAYTU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of AYTU (1.32%) is better than 82.20% of its industry peers.
With an excellent Return On Equity value of 4.70%, AYTU belongs to the best of the industry, outperforming 84.29% of the companies in the same industry.
AYTU's Return On Invested Capital of 0.46% is fine compared to the rest of the industry. AYTU outperforms 78.01% of its industry peers.
Industry RankSector Rank
ROA 1.32%
ROE 4.7%
ROIC 0.46%
ROA(3y)-35%
ROA(5y)-27.17%
ROE(3y)-112.19%
ROE(5y)-78.65%
ROIC(3y)N/A
ROIC(5y)N/A
AYTU Yearly ROA, ROE, ROICAYTU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

AYTU has a Profit Margin of 2.37%. This is amongst the best in the industry. AYTU outperforms 81.15% of its industry peers.
The Operating Margin of AYTU (0.53%) is better than 78.01% of its industry peers.
With a decent Gross Margin value of 68.59%, AYTU is doing good in the industry, outperforming 76.44% of the companies in the same industry.
In the last couple of years the Gross Margin of AYTU has remained more or less at the same level.
Industry RankSector Rank
OM 0.53%
PM (TTM) 2.37%
GM 68.59%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.82%
GM growth 5Y-0.72%
AYTU Yearly Profit, Operating, Gross MarginsAYTU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

1

2. Health

2.1 Basic Checks

AYTU has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
There is no outstanding debt for AYTU. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AYTU Yearly Shares OutstandingAYTU Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
AYTU Yearly Total Debt VS Total AssetsAYTU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

AYTU has an Altman-Z score of -2.80. This is a bad value and indicates that AYTU is not financially healthy and even has some risk of bankruptcy.
AYTU has a Altman-Z score (-2.80) which is in line with its industry peers.
A Debt/Equity ratio of 0.56 indicates that AYTU is somewhat dependend on debt financing.
The Debt to Equity ratio of AYTU (0.56) is worse than 64.40% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF N/A
Altman-Z -2.8
ROIC/WACC0.03
WACC15%
AYTU Yearly LT Debt VS Equity VS FCFAYTU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 1.03 indicates that AYTU should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.03, AYTU is doing worse than 81.15% of the companies in the same industry.
AYTU has a Quick Ratio of 1.03. This is a bad value and indicates that AYTU is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of AYTU (0.87) is worse than 79.58% of its industry peers.
Industry RankSector Rank
Current Ratio 1.03
Quick Ratio 0.87
AYTU Yearly Current Assets VS Current LiabilitesAYTU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 11.54% over the past year.
EPS 1Y (TTM)11.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-256.1%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-15.8%

3.2 Future

The Earnings Per Share is expected to grow by 50.54% on average over the next years. This is a very strong growth
AYTU is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.87% yearly.
EPS Next Y65.73%
EPS Next 2Y50.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-9.89%
Revenue Next 2Y3.56%
Revenue Next 3Y10.25%
Revenue Next 5Y14.87%

3.3 Evolution

AYTU Yearly Revenue VS EstimatesAYTU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M
AYTU Yearly EPS VS EstimatesAYTU Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -50K -100K -150K

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AYTU. In the last year negative earnings were reported.
Also next year AYTU is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AYTU Price Earnings VS Forward Price EarningsAYTU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

100.00% of the companies in the same industry are more expensive than AYTU, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 2.46
AYTU Per share dataAYTU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

AYTU's earnings are expected to grow with 50.54% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.54%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AYTU!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AYTU BIOPHARMA INC

NASDAQ:AYTU (10/23/2025, 10:44:43 AM)

2.25

-0.02 (-0.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)09-23 2025-09-23/amc
Earnings (Next)11-11 2025-11-11
Inst Owners38.09%
Inst Owner Change0%
Ins Owners8.18%
Ins Owner Change1.64%
Market Cap22.30M
Revenue(TTM)N/A
Net Income(TTM)1.64M
Analysts82.22
Price Target9.35 (315.56%)
Short Float %5.63%
Short Ratio2.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)115.04%
Min EPS beat(2)8.96%
Max EPS beat(2)221.11%
EPS beat(4)3
Avg EPS beat(4)94.57%
Min EPS beat(4)-78.65%
Max EPS beat(4)226.87%
EPS beat(8)6
Avg EPS beat(8)-375.67%
EPS beat(12)8
Avg EPS beat(12)-262.38%
EPS beat(16)9
Avg EPS beat(16)-226.19%
Revenue beat(2)2
Avg Revenue beat(2)16.96%
Min Revenue beat(2)2.24%
Max Revenue beat(2)31.67%
Revenue beat(4)3
Avg Revenue beat(4)11.43%
Min Revenue beat(4)-3.7%
Max Revenue beat(4)31.67%
Revenue beat(8)6
Avg Revenue beat(8)4.72%
Revenue beat(12)8
Avg Revenue beat(12)2.67%
Revenue beat(16)9
Avg Revenue beat(16)1.15%
PT rev (1m)-5.17%
PT rev (3m)1.85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-22.23%
EPS NY rev (1m)0%
EPS NY rev (3m)-8.33%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.59%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.4%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.32
P/FCF N/A
P/OCF N/A
P/B 0.64
P/tB N/A
EV/EBITDA 2.46
EPS(TTM)-2.53
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.56
OCFYN/A
SpS6.99
BVpS3.52
TBVpS-1.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 1.32%
ROE 4.7%
ROCE 0.69%
ROIC 0.46%
ROICexc 0.64%
ROICexgc N/A
OM 0.53%
PM (TTM) 2.37%
GM 68.59%
FCFM N/A
ROA(3y)-35%
ROA(5y)-27.17%
ROE(3y)-112.19%
ROE(5y)-78.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.82%
GM growth 5Y-0.72%
F-Score4
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF N/A
Debt/EBITDA 3.06
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 0.13
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.03
Quick Ratio 0.87
Altman-Z -2.8
F-Score4
WACC15%
ROIC/WACC0.03
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-256.1%
EPS Next Y65.73%
EPS Next 2Y50.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-15.8%
Revenue Next Year-9.89%
Revenue Next 2Y3.56%
Revenue Next 3Y10.25%
Revenue Next 5Y14.87%
EBIT growth 1Y-80.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year402.12%
EBIT Next 3Y131.97%
EBIT Next 5Y59.65%
FCF growth 1Y73.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y74.38%
OCF growth 3YN/A
OCF growth 5YN/A